Progyny, Inc. (PGNY)
NASDAQ: PGNY · IEX Real-Time Price · USD
+0.77 (2.73%)
At close: Jul 12, 2024, 4:00 PM
+0.05 (0.17%)
After-hours: Jul 12, 2024, 7:50 PM EDT

Company Description

Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions in the United States.

Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.

The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment.

In addition, it provides assistance service programs where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services.

The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.

Progyny, Inc.
Progyny logo
Country United States
IPO Date Oct 25, 2019
Industry Health Information Services
Sector Healthcare
Employees 566
CEO Peter Anevski

Contact Details

1359 Broadway, 2nd Floor
New York, New York 10018
United States
Phone 212-888-3124

Stock Details

Ticker Symbol PGNY
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $13.00
CIK Code 0001551306
CUSIP Number 74340E103
ISIN Number US74340E1038
Employer ID 27-2220139
SIC Code 8090

Key Executives

Name Position
Peter Anevski Chief Executive Officer and Director
David J. Schlanger Executive Chairman
Michael Sturmer President
Mark S. Livingston Chief Financial Officer
Allison Swartz General Counsel and Secretary
Steven Leist Chief Technology Officer
James Hart Vice President of Investor Relations
Risa Fisher Chief Marketing Officer
Cassandra Pratt Chief Human Resources Officer
Julie Stadlbauer Chief Business Development Officer

Latest SEC Filings

Date Type Title
Jun 28, 2024 144 Filing
May 29, 2024 8-K Current Report
May 22, 2024 8-K Current Report
May 10, 2024 10-Q Quarterly Report
May 9, 2024 8-K Current Report
May 1, 2024 144 Filing
Apr 12, 2024 ARS Filing
Apr 12, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 12, 2024 DEF 14A Other definitive proxy statements
Apr 1, 2024 144 Filing